Recent Updates
Recently added Catalysts
CGEM Positive Sentiment

Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer

Wednesday, August 12, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics announced that their Phase 3 REZILIENT3 trial has successfully met its primary endpoint of progression-free survival. This trial evaluates the efficacy of zipalertinib in combination with chemotherapy for patients with EGFR Exon 20 insertion mutation non-small cell lung cancer. The results from this interim analysis are promising for future treatment options.

Market Sentiment Analysis

POSITIVE FACTORS

  • Zipalertinib combined with chemotherapy met primary endpoint.
  • The trial focuses on a significant patient population with EGFR mutations.
  • Positive interim analysis results could lead to further advancements in treatment.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+93%
120-day peak, hindsight
Typical move
6.7%
average across 8 past catalysts
Cash runway
~18 mo
Low dilution risk
Lead asset
CLN-619
Phase 1 · Multiple Myeloma

Full Press Release Details

PRINCETON, New Jersey, TOKYO, Japan, CAMBRIDGE, Mass., August 12, 2026 — Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced that the REZILIENT3 trial, a global Phase 3 clinical trial evaluating the combination of zipalertinib and

Frequently Asked Questions

What is the REZILIENT3 trial?

The REZILIENT3 trial is a global Phase 3 clinical study evaluating zipalertinib with chemotherapy.

What endpoint did the REZILIENT3 trial meet?

The trial met its primary endpoint of progression-free survival.

Who are the companies involved in the trial?

The trial involves Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics.

What type of cancer is being targeted in the trial?

The trial targets non-small cell lung cancer with EGFR Exon 20 insertion mutations.

ShareAdd on Google
Tags: CGEM Viatris Investor Conferences Healthcare zipalertinib lung cancer EGFR mutation clinical trial
Last updated: Aug 12, 2026

Biotech snapshot

Cash runway
$335M liquidity · $19M/mo burn
~18 mo
Low dilution risk
Lead asset
CLN-619Phase 1
Multiple Myeloma →

Catalyst track record

+93%
best trade around CGEM's most recent catalyst

Peak hindsight return over a 120-day window, across 8 tracked FDA/PDUFA catalysts for CGEM.

See every catalyst's timing & PoA →